1 Tumor Purity-Related Genes for Predicting the Prognosis and Drug Sensitivity

2 of DLBCL Patients

- ³ Zhenbang Ye^{1#}, Ning Huang^{2#}, Yongliang Fu¹, Rongle Tian¹, Liming Wang^{2*}, Wenting Huang^{1,3*}
- 4 ¹Department of Pathology, National Cancer Center/National Clinical Research Center for
- 5 Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical
- 6 College, Beijing, China;
- ⁷ ²Department of Hepatobiliary Surgery, National Cancer Center/National Clinical Research Center
- 8 for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical
- 9 College, Beijing 100021, China
- ³Department of Pathology, National Cancer Center/National Clinical Research Center for
- 11 Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking
- 12 Union Medical College, Shenzhen, 518116, China.
- 13 #These authors contributed equally to this work.
- 14 *Corresponding author
- 15 Wenting Huang, Ph.D.
- 16 Department of Pathology, National Cancer Center/National Clinical Research Center for
- 17 Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical
- 18 College, Beijing, China; No. 17 Panjiayuan Nanli, Chaoyang Dist., Beijing, PRC.
- 19 Department of Pathology, National Cancer Center/National Clinical Research Center for
- 20 Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking
- 21 Union Medical College, Shenzhen, 518116, China; No. 113 Baohe Ave. Longgang Dist. Shenzhen,
- 22 PRC.
- 23 E-mail: huangwt@cicams.ac.cn
- 24
- 25 Liming Wang, M.D.
- 26 Department of Hepatobiliary Surgery, National Cancer Center/National Clinical Research Center
- 27 for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical
- 28 College, No. 17 PanjiayuanNanli Road, Chaoyang District, Beijing 100021, China
- 29 Email: stewen_wang@sina.com
- 30

31 Abstract

- 32 Background: Diffuse large B-cell lymphoma (DLBCL) is the predominant type of malignant
- 33 B-cell lymphoma. Although various treatments have been developed, the limited efficacy calls for
- 34 more and further exploration of its characteristics.
- 35 Methods: Datasets from Gene Expression Omnibus (GEO) database were used for identifying the
- 36 tumor purity of DLBCL. Survival analysis was employed for analyzing the prognosis of DLBCL
- 37 patients. Immunohistochemistry was conducted to detect the important factor that influenced the
- prognosis. Drug sensitive prediction was performed to evaluate the value of the constructedmodel.
- 40 Results: VCAN, CD3G and C1QB were identified as three key genes that impacted the outcome 41 of DLBCL patients both in GEO datasets and samples from our center. Among them, VCAN and 42 CD3G+ T cells were correlated with favorable prognosis, and C1QB was correlated with worse 43 prognosis. The ratio of CD68+ macrophages and CD8+ T cells was associated with better 44 prognosis. In addition, CD3G+ T cells ratio was significantly correlated with CD68+ macrophages, 45 CD4+ T cells and CD8+ T cells ratio, indicating it could play an important role in the anti-tumor 46 immunity in DLBCL. The riskScore model constructed based on the RNASeq data of VCAN, 47 C1QB and CD3G work well in predicting the prognosis and drug sensitivity.
- 48 Conclusion: VCAN, CD3G and C1QB were three key genes that influenced the tumor purity of
- 49 DLBCL, and could also exert certain impact on drug sensitivity and prognosis of DLBCL patients.
 50
- 51 Keywords: DLBCL, tumor purity, VCAN, CD3G, C1QB
- 52

53 Introduction

The latest refined classification by the World Health Organization (WHO) categorizes large B-cell lymphoma as a heterogeneous group of B-cell lymphomas[1]. Diffuse large B-cell lymphoma (DLBCL) is the most prevalent type among them, accounting for around 30% of all non-Hodgkin lymphomas. DLBCL can be classified into three subtypes based on its immunohistochemical expression patterns: germinal center B-cell-like (GCB), activated B-cell-like (ABC), and unclassified[2]. Moreover, an additional classification is established by evaluating the immunohistochemical expression patterns according to Hans algorithm, leading to two subtypes:

61 GCB and non-GCB[3]. After undergoing R-CHOP chemotherapy, about 60% of patients achieve 62 long-term remission; however, approximately 30% of patients experience relapse, resulting in 63 poor prognosis and a considerable number of deaths from refractory lymphoma[4]. Consequently, 64 to explore the characteristics of DLBCL in detail is urgently needed for developing more effective 65 therapy.

66 Solid tumor tissue comprises tumor cells and the surrounding stroma, which encompasses 67 diverse types of matrix cells, immune cells, endothelial cells[5], etc. The tumor microenvironment 68 (TME) is a complex and dynamic system that consists of the extracellular matrix and a variety of 69 cellular components. Recent studies have unveiled multiple subgroups of immune cells within the 70 microenvironment of DLBCL, including T cells, B cells, NK cells, monocytes/macrophages, 71 dendritic cells, as well as the distribution of stromal cell components like fibroblasts and 72 endothelial cells [6, 7]. Despite the relatively limited composition of the TME in DLBCL, its role 73 in tumor proliferation and evasion of the immune system should not be disregarded. The 74 interaction between tumors and the microenvironment is a vital factor that impacts the 75 development and prognosis of B-cell lymphoma[8]. Nevertheless, the existing research on the 76 influence of the TME on the prognosis of DLBCL patients is limited and lacks a consensus.

77 Moreover, the comprehensive investigation of non-immune cell components in the TME is still 78 lacking. Previous research on stroma in DLBCL has predominantly indicated that a higher 79 quantity of extracellular matrix is associated with a more favorable prognosis, while increased 80 vascular density is associated with poorer prognosis[9]. Furthermore, higher stromal scores have 81 been associated with an improved prognosis in DLBCL patients[10]. Additionally, a fibrotic tumor 82 microenvironment has been correlated with a better prognosis after DLBCL chemotherapy and 83 immunotherapy[11]. These research findings stem from computational analysis of stromal and 84 immune scoring in gene databases and have not been experimentally validated as of yet.

Tumor purity quantifies the relative ratio of tumor cells to the surrounding stromal components in solid tumors, elucidating the dynamics between tumor cells and their microenvironment[12]. It can partly reflect the characteristics of TME, namely, a higher tumor purity indicates a lower abundance of stromal components in TME. Tumor purity is associated with patient prognosis, and the strength of this association varies across different tumor types[13-15]. Therefore, when investigating the influence of TME on the prognosis of DLBCL, it is crucial to analyze not only

91 the immune cell components but also the significance of non-immune cell components.

This study utilized bioinformatic analysis to establish the relationship between immune and stromal components and the prognostic outcomes of DLBCL patients. We developed a novel immunohistochemical panel to assess prognostic outcomes and treatment sensitivity by detecting the expression of VCAN, CD3G, C1QB, CD68, CD4 and CD8 in both the TME and tumor cells of 190 DLBCL patients. We then explored their relationship with DLBCL clinicopathological features as well as overall survival (OS).

98

99 Materials and Methods

100 Data collection and tumor purity-related genes (TPGs) selection

The RNA-Sequence and clinical data of GSE53786 and GSE32918 datasets were download from Gene Expression Omnibus (GEO) database. The first gene symbols of GSE53786 datasets were retained when one probe detected multiple genes. Average expression value of genes in each dataset were calculated and used when one gene was detected by multiple probes. Tumor purity was assessed by ESTIMATE (Estimation of Stromal and Immune cells in Malignant Tumor tissues using Expression data) algorithm[16] and the then its correlation with genes expression was analyzed. The genes with $|r| \ge 0.5$ and p value < 0.05 was defined as the TPGs.

108

109 **TPGs function analysis**

Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses were executed to analyze the biological processes, cellular components, molecular functions and pathways related to the TPGs. The statistical significance was considered as p.adjust < 0.05.

TPGs, and those with interactive confidence greater than 0.90 on the STRING platform (version 11.5) were selected to establish an interaction network with Cytoscape software (version 3.8.2).

116

117 **Prognostic model**

The prognostic model was constructed with "survival" package in R (version 4.1.3). The genes enrolled in this model was selected among the prognostic and PPI hub TPGs by function "step" in "survival" package, which can optimize the model. The prognostic model was represented by

121 riskScore = $\sum_{i=1}^{n}$ gene expression_i × coef_i.

122

123 Clinical specimens and follow-up

124 190 patients from Cancer hospital Chinese Academy of Medical Sciences, the CHCAMS cohort, 125 were enrolled in this study (Supplementary table 1). All patients received surgery or biopsy 126 during September, 2010 and September, 2020, and then standard follow-ups were carried out until 127 March, 2023. The overall survival (OS) was defined as the interval between the operation and 128 death or the last follow-up. The specimens from the CHCAMS cohort were used for 129 immunohistochemistry assay. The study was designed according to the Declaration of Helsinki 130 and approved by the institutional ethics committee of Cancer Hospital Chinese Academy of 131 Medical Sciences. Informed consent was taken from all the patients.

132

133 **IHC**

134 Paraffin embedded DLBCL tissues of CHCAMS Cohort were used for immunohistochemistry 135 (IHC). After de-paraffinization and hydration, heat-induced method was performed for antigen 136 retrieval. Primary antibody of VCAN (AB177480, 1:100, Abcam, USA), CD3G (AB134096, 137 1:1000, Abcam, USA), C1QB (AB92508, 1:50, Abcam, USA), CD68 (303565, 1:1000, Abcam, 138 USA), CD4 (ZM-0418, ZSGB-BIO, China), CD8 (ZA-0508, ZSGB-BIO, China), CD206(24595S, 139 1:400, CST, USA), and CD32(15625-1-AP, 1:1000, proteintech, China) was incubated at 4°C 140 overnight. Sections were washed with TBS-T buffer, and then incubated with secondary antibody, 141 and finally stained with DAB. The quantitative analysis of the slices was conducted by 142 QuPath-0.4.3. VCAN and C1QB were assessed by H-score, and CD3G, CD68, CD4, CD8, CD206, 143 CD32 were assessed as the ratio of the corresponding positive cells among all cells.

144

145 **Drug sensitivity prediction**

Drug sensitivity prediction was conducted utilizing "oncoPredict" packages in R 4.1.3. The drug sensitivity data was collected from Genomics of Drug Sensitivity in Cancer (GDSC). The drugs that was analyzed in this study was selected according to clinical practice or clinical trials searched in Pubmed.

151 Statistical analysis

152Data in this study was shown in the form of mean \pm SEM. Correlation between two variates was 153 determined with Spearman analysis. Kaplan–Meier (K–M) curve and Log rank test were used 154 for survival analysis. The cut-offs of survival analysis were provided by X-tile. The 155 independent risk factor analysis was performed with Cox regression analysis. Receiver 156 operating characteristic (ROC) curve was used for test the efficacy of prognostic model. The clinicopathological characteristics difference analysis was conducted with χ^2 test, Fisher's 157 158 exact test or Wilcoxon rank sum test. The drug sensitivity scores were compared with 159Wilcoxon rank sum test. In this study, p < 0.05 were considered statistically significant.

160

161 Results

162 Tumor purity related genes were correlated with extracellular matrix organization and 163 immune response

Based on GSE53786 dataset, we first assessed the tumor purity of DLBCL, which ranged from 17.2% to 67.4% (**Figure 1A**). In order to screen out the TPGs, we then analyzed the correlation between genes expression and tumor purity. According to the thresholds mentioned above, 642 genes were identified as TPGs, among which 31 genes were positively correlated with tumor purity, while 611 genes were negatively correlated with it (**Figure 1B**). In addition, tumor purity did have influence on the prognosis of DLBCL patients, which showed that patients with high tumor purity had lower OS rate than those with low tumor purity (**Figure 1C**, p = 0.025).

171 Next, we performed GO and KEGG enrichment analyses to explore the functions and signaling 172 pathways in which these TPGs were involved. It turned out that the TPGs were mainly associated 173 with extracellular matrix organization and immune response (**Figure 1C, 1D**). Not only did the 174 enrichment results confirm that these genes were reliable to be related with the tumor purity, but it 175 also laid solid foundations for the sequent analyses.

176

177 A prognostic model was constructed with three TPGs

With the 642 TPGs, we exerted PPI analysis to investigate their interaction and the hub genes (Figure 2A). The TPGs who had five or more interactive genes were shown in Figure 2B, and defined as hub genes. Then, we performed univariate Cox regression analysis to figure out the

TPGs that were associated with the prognosis of DLBCL patients, and 103 genes were identified (**Figure 2C**). Interestingly, most of the TPGs were correlated with good outcome (with HR < 1), and only six genes were associated with poor outcome (with HR > 1). Through conducting intersection analysis, we found nine genes (LUM, VCAN, YAP1, COL5A2, SDC2, TWIST1, CD3G, C1QB and C3) were intersection genes, indicating that they had an active effect in modulating the tumor purity, as well as influencing the prognosis of DLBCL patients.

187 After ascertaining the key genes, we tried to construct a prognostic model with them. The model 188 was constructed by Cox regression, and the three selected genes (VCAN, CD3G, C1QB) and their 189 parameters like coefficient, HR and 95%CI of HR, were shown in Figure 3A. It showed that 190 VCAN and CD3G were correlated with good prognosis and C1QB was correlated with poor 191 prognosis. All patients were divided into high and low-risk group according to the median value of 192 riskScore (Figure 3B). As expected, the high-risk group has worse prognosis than the low-risk 193 group (Figure 3C). In addition, the three genes were differentially expressed between high and 194 low-risk group, with VCAN and CD3G showing high expression level in low-risk group, and 195 C1QB showing high expression level in high-risk group, which was consistent with the coefficient 196 (Figure 3D). To appraise the efficacy of these prognostic model, we conducted survival analysis 197 and ROC analysis. High-risk group had lower OS rate than low-risk group (**Figure 3E**, p < 0.001), 198 and the areas under curve (AUC) for 1-year, 3-year and 5-year ROC were 0.73, 0.77 and 0.77 199 respectively (Figure 3F). Just similar to tumor purity, the high riskScore indicated bad outcome, 200 which was consistent with the positive correlation between tumor purity and riskScore (Figure 201 **3G**). This TPGs signature prognostic model manifested satisfying prognostic efficacy.

202 When we applied this model to GSE32918 dataset, it still did excellently and the results were in 203 accordance with that in GSE53786 dataset (Figure 4A, 4B; Supplementary Figure 2). Next, we 204 analyzed the relationship between riskScore and some clinicopathological characteristics provided 205 in GSE53786 dataset. The results showed that high-risk group had more ABC type DLBCL, while 206 low-risk group had more the GCB type DLBCL (Figure 4C). Besides, high-risk group displayed 207 higher lactic dehydrogenase (LDH) ratio (Figure 4F). However, the Eastern Cooperative 208 Oncology Group (ECOG) performance and stage was not associated with the riskScore (Figure 209 4D, 4E). Still, the high-risk group has more Stage III and Stage IV patients, but less Stage I 210 patients than low-risk group. Finally, we employed the univariate and multivariate analysis to

explore whether riskScore was an independent prognostic factor for DLBCL patients. As expected,
the riskScore was associated with the poor prognosis (Figure 4G, p < 0.001, HR = 1.545, 95%CI
1.284–1.861) and was an independent prognostic factor (Figure 4H, p = 0.002, HR = 1.474,
95%CI 1.156–1.879).

215

216 The prognostic value of VCAN, CD3G and C1QB were validated by IHC assay

217 With the purpose of the further validation of the prognostic value of VCAN, CD3G and C1QB, we 218 detected the expression of these genes in CHCAMS cohort by IHC. For VCAN, the patients were 219 divided into high and low group according to the cut-off of the H-score (275.42) provided by 220 X-tile. The survival analysis showed that patients with high expression of VCAN had higher OS 221 rate (Figure 5A, p = 0.003). For CD3G, previous study revealed that it was a component of T cell 222receptor complex, for which it could be regarded as a marker of T cells[17]. Therefore, we 223 assessed the expression level of CD3G by counting the CD3G+ T cells ratio, and divided patients 224 by the cut-off (2.5%). The survival analysis revealed that patients with high CD3G+ T cells 225 infiltration showed favorable prognosis (Figure 5B, p < 0.001). For C1QB, the patients in high 226 expression group (cut-off = 82.41) showed adverse prognosis (Figure 5C, p = 0.015). Although 227 the detection of protein level was not convenient to build a prognostic model for the difference of 228 assessment methods and the lake of coefficient, these results were in accordance with those of 229 GEO datasets, which successfully proved the prognostic value of VCAN, CD3G and C1QB.

230 Given that these genes could potentially influence the tumor purity of DLBCL, we then analyzed 231 the relationship between them and CD68+ macrophages, CD4+ T cells and CD8+ T cells. As was 232 shown in Supplementary figure 3A, CD68+ macrophages [(17.75±1.05) %] account for more 233 ratio than CD4+ T cells $[(0.68\pm0.20) \%]$ and CD8+ T cells $[(6.69\pm0.56) \%]$ (p < 0.001, 234 Kruskal-Wallis Test and Dunn's Test). In the survival analysis of these three types of immune cells, 235 we found that CD68+ macrophages, CD8+ T cells and CD4+ T cells were associated with better 236 prognosis (Figure 5D–F, p = 0.029, p = 0.002, p = 0.053). And XCELL and QUANTISEQ 237 algorithm revealed that M1 macrophages accounted for more proportion than M2 macrophages in 238GSE53786 and GSE32918 (Supplementary figure 3L-O), which was confirmed in the 239 CHCAMS cohort (Supplementary figure 3P). Besides, the ratio of CD3G+ T cells was positively 240 correlated with that of CD68+ macrophages, CD8+ T cells and CD4+ T cells, C1QB expression

level was positively correlated with CD8+ T cells, and VCAN expression level was positively
correlated with CD8+ T cells ratio (Figure 5G). GSEA analysis based on the differentially
expressed genes between high-risk and low-risk group in the GEO datasets above revealed that the
cellular adhesion, extracellular structures and immune-related processes could result in the
different outcome (Figure 5H–I)
In addition to the above analyses, we also explored the relationship between these three genes and

- 247 location of DLBCL. It turned out that CD3G+ T cells ratio was higher in DLBCL originated from
- groin and testis, and VCAN featured higher expression in lymph node originated DLBCL (Figure
- 249 **5J–K**, p < 0.05, p < 0.01, **Supplementary figure 3B–K**).
- These results showed that VCAN, CD3G and C1QB played important roles in the microenvironment of DLBCL, possibly regulating the immune infiltration via modulating the extracellular organization and cellular interaction.
- 253

254 The TPGs signature model could also predict the drug sensitivity of DLBCL patients

In order to learn about the ability of the previously mentioned model to predict drug sensitivity, we performed the prediction with "oncoPredict" package in R. Fifteen drugs (**Supplementary table 2**) included in the GDSC and used in clinical practice or under clinical trials (searched on Pubmed) were enrolled in this prediction analysis.

259As is shown in Figure 6A (prediction of GSE53786), patients in high-risk group could be 260 sensitive to Carmustine, Cytarabine, Oxaliplatin, Vincristine, Vorinostat, and Bortezomib, but no 261 drug could work better in low-risk group. And in GSE32918 (Figure 6B), Carmustine, Cytarabine, 262 Oxaliplatin, Vorinostat, Afuresertib, Bortezomib, Ibrutinib and Tamoxifen could work better in 263 high-risk group, and Vincristine (sensitivity score: low-risk vs high-risk = 0.219 ± 0.026 vs 264 0.223 ± 0.031) could work better in low-risk group. The discrepancy between the prediction in two 265 datasets might be due to the samples and sequencing platforms. However, the intersection analysis 266 of the drugs to which the high-risk patients in both datasets could be sensitive revealed that 267 Carmustine, Cytarabine, Oxaliplatin, Vorinostat and Bortezomib could be reliable candidates for 268 treating high-risk patients based on the three TPGs signature prognostic model (Supplementary 269 table 2).

271 Discussion

272In this study, bioinformatics techniques were employed to identify three genes (VCAN, CD3G, 273 C1QB) that exhibit associations with prognosis in both immune and stromal environments, 274 thereby revealing their relationship with the prognosis of DLBCL patients. The findings indicate 275that higher expression of VCAN, increased infiltration of CD3G+ T cells, and decreased 276 expression of C1QB are correlated with favorable prognostic outcomes. Conversely, a lower 277 infiltration of CD68+ macrophages and lower infiltration of CD8+ T cells are associated with 278 poorer prognosis. Furthermore, we investigated the relationship between risk genes related to 279 tumor purity and treatment sensitivity and established a list of possible drugs that might be helpful 280 for enhancing outcomes.

281 Previous studies have extensively investigated the VCAN gene in relation to tumorigenesis and 282metastasis[18]. VCAN, also known as versican, is a crucial component of extracellular matrix[19], 283 and exists in several isoforms[20]. Research has shown that VCAN plays a multifaceted role in 284 TME depending on the cell type expressing it. When expressed by myeloid cells, VCAN induces 285 an anti-inflammatory and immunosuppressive microenvironment. Conversely, its expression by 286 stromal cells typically leads to a pro-inflammatory response[21]. In gastric cancer, high expression 287 of VCAN has been associated with increased infiltration of fibroblasts, significant enrichment of 288 stromal-associated signaling pathways and poor prognosis[22]. In hepatocellular carcinoma, 289 VCAN exhibits a strong association with immune checkpoint gene expression[23]. Despite these 290 findings in other tumor types, the role of VCAN in DLBCL has not been explored yet. Our study 291 reveals that high expression of VCAN is actually associated with a more favorable prognosis. This 292 suggests that VCAN may have different functions in different tumor types. One possible 293 mechanism through which VCAN influences prognosis is that VCAN overexpression in DLBCL 294 may also impact tumor cell proliferation. A study has shown that overexpression of VCAN V1 has 295 an inhibitory effect on cell proliferation, partly due to its promotion of activation-induced cell 296 death in lymphoid cell lines[20]. Hence, the high expression of VCAN in DLBCL could impact 297 not only the TME but also tumor cell proliferation, suggesting a potential mechanism for the 298observed preferable prognosis.

C1q is synthesized in the tumor microenvironment and functions as an extracellular matrix protein,
and C1QB is a component of C1q[24]. Previous studies have provided insights into the diverse

301 roles of C1q in cancer progression. However, the majority of these results, as observed in 302 non-small cell lung carcinoma and gastric cancer, indicate that high C1q expression in TME is 303 associated with a poor prognosis [25-27]. Additionally, C1QB has been found to exert an impact 304 on the TME and is positively associated with infiltration levels of CD8+ T cell, as well as with M1 305 and M2 macrophages in osteosarcoma[28]. Moreover, C1QB expression shows a positive 306 correlation with predictive biomarkers for immunotherapy, such as PD-L1 expression and CD8+T 307 cell infiltration[27]. Furthermore, in malignant melanoma, C1QB promotes proliferation, 308 migration and invasion, while inhibiting cell apoptosis[29], and the high-expression group exhibits 309 significant enrichment of genes related to immune and apoptosis[24]. In our study, we found that 310 high expression of C1QB in DLBCL was associated with a worse prognosis and positively 311 correlated with CD8+ T cells infiltration. Based on these findings, we propose that C1QB in 312 DLBCL might share similarities with its functions in other tumor types, particularly regarding the 313 promotion of recruitment and subsequent deactivation of CD8+ T cells within the TME through 314 the induction of immune checkpoint effects. These results shed light on the intricate role of C1QB 315 in TME and its potential significance as a prognostic marker in DLBCL.

316 CD3G is a member of the TCR/CD3 complex primarily expressed in lymphocytes subgroups. It 317 plays a crucial role in initiating the activation of T cells[17]. It is also involved in coupling antigen 318 recognition[30]. It is reported to associate with long-term OS and good prognosis in breast 319 invasive carcinoma[31] as well as in head and neck squamous cell carcinoma[32]. However, its 320 role in DLBCL has not been fully explored. In our study, we revealed that high infiltration of 321 CD3G+ T cells is correlated with good prognosis. The infiltration of CD3G+ T cells was found to 322 be positively related to the infiltration of CD8+, CD4+ and CD68+ cells. This indicates that 323 CD3G+ T cells in DLBCL may enhance the tumor antigen recognition process and stimulate the 324 infiltration of immune cells, leading to an increased abundance of immune cell infiltration in the 325 TME. The presence of CD3G+ T cells in the TME may contribute to a favorable prognosis by 326 facilitating the activation of immune responses against tumor cells.

Macrophages play a crucial role in TME, and CD68 is a surface marker specific to macrophages. Macrophages can be roughly classified into two types based on their functional features: M1 or M2. M1 macrophages exert anti-tumor effects, whereas M2 macrophages promote tumor growth and progression in TME[33]. A previous study found that low infiltration of CD68+ macrophages

was associated with an inferior prognosis[34]. Similarly, our study has yielded similar results, revealing a noteworthy correlation between a high proportion of CD68+ macrophages in the TME and improved prognosis. Additionally, by analyzing the datasets, we observed a higher proportion of M1 macrophages infiltration compared to M2 macrophages. This suggests that, within our DLBCL cohort, these macrophages may also exhibit the M1 phenotype and consequently play a protective role against tumor progression.

337 CD8 is widely recognized as a marker of CD8+ T cells, also known as cytotoxic T cells[35]. 338 These cells are crucial for the immune response against tumors. However, in DLBCL, CD8+ T 339 cells exhibits elevated levels of inhibitory molecules on their surface, such as PD-1, PD-L1, TIM3. 340 High expression of TIM3, an inhibitory immune checkpoint receptor, on CD8+ T cells has been 341 associated with tumor progression and poor outcomes [36, 37]. These inhibitory molecules may 342 impair the function of CD8+ T cells and hinder their anti-tumor activity. Surprisingly, our study 343 demonstrates a correlation between the infiltration of CD8+ T cells and favorable prognosis in 344 DLBCL. Here, we propose a hypothesis that in our study, the observed high expression of VCAN 345 might create a suppressive environment for PD-1+ CD8+ T cells[21, 38]. Intriguingly, our study 346 revealed a statistically significant correlation between VCAN expression, C1QB expression and 347 CD8+ T cell infiltration. VCAN has the potential to modulate immune infiltration by reducing the 348 immunosuppressive phenotype of immune cells[39], thus enabling a more efficient anti-tumor 349 response. This aspect is still worth of consideration.

Taken together, our findings underscore the significant roles of VCAN, CD3G, C1QB, which influence both the TME and the behavior of tumor cells. The interaction between each component and the TME is rather complicated. To fully comprehend the underlying mechanisms and identify potential therapeutic targets in DLBCL, further investigation is required.

However, this study still has several limitations that should be addressed. Firstly, the patients included in this study were form a single center, which may introduce biases into the results. Although we made efforts to minimize these biases, it is inevitable that some may persist. Secondly, we hypothesized that VCAN, CD3G and C1QB could serve as continuous prognostic parameters, thereby eliminating the need for a cut-off. However, the methodology used in this study, which utilized IHC staining to assess the protein expression levels, may have potential limitations. While IHC is a widely used technique, additional validation is needed to confirm the

361 prognostic value of VCAN, CD3G and C1QB in DLBCL. Furthermore, due to the potential 362 variability in interpreting IHC results across different centers, a standardized coefficient and 363 formula have not been established to calculate the final prognostic index for patients with DLBCL. 364 Developing a standardized approach would be beneficial in ensuring consistent and accurate 365 interpretation of IHC results. To address these limitations and expand upon our findings, future 366 studies should strive to incorporate a diverse range of patients from multiple centers. Additionally, 367 it is crucial to employ rigorous experimental techniques to authenticate the prognostic significance 368 of VCAN, CD3G, and C1QB in DLBCL.

369

370 Author contributions

Conceptualization: Wenting Huang, Ning Huang, Zhenbang Ye, Data Curation: Zhenbang Ye,
Ning Huang, Formal Analysis: Zhenbang Ye, Ning Huang, Liming, Wang, Investigation:
Zhenbang Ye, Methodology: Zhenbang Ye, Ning Huang, Wenting Huang, Liming Wang,
Resources: Wenting Huang, Yongliang Fu, Liming Wang, Supervision: Wenting Huang, Liming
Wang, Visualization: Zhenbang Ye, Ning Huang, Validation: Ning Huang, Writing-Original Draft:
Zhenbang Ye, Ning Huang, Writing-Review & Editing: Wengting Huang, Yongliang Fu, Rongle
Tian.

378

379 Funding

This work is supported by Shenzhen High-level Hospital Construction Fund and CAMS Innovation Fund for Medical Sciences (CIFMS) (2022-I2M-C&T-B-062). The funders had no role in study design, data collection and analysis, interpretation of data, or preparation of the manuscript.

384

- 385 Acknowledgement
- 386 Not applicable.

387

388 Conflicts of interest

389 The authors made no disclosures.

391 Figure 1 TPGs were screened out with GSE53786 dataset.

(A) The range (17.2 –67.4%) of tumor purity of samples in GSE53786. (B) The heatmap showing
genes defined as TPGs. (C) The K–M curve showed high tumor purity was correlated with poor
prognosis in DLBCL patients in GSE53678 dataset (Patients were divided into two groups
according to the best-cutoff provided by "survminer" package in R). (D) GO analysis of TPGs.
(E) KEGG analysis of TPGs. TPGs, tumor purity-related genes; K–M, Kaplan-Meier;
DLBCL, diffuse large B cell lymphoma; GO, gene ontology; KEGG, Kyoto Encyclopedia of
Genes and Genomes.

399 Figure 2 The key gene candidates used for constructing prognostic model were selected.

(A) The PPI network of TPGs (orange nodes representing genes positively correlated with tumor purity, and green nodes representing genes negatively correlated with tumor purity). (B) The barplot showing hub genes with five or more interactive genes. (C) The forest plot showing prognostic TPGs of DLBCL patients in GSE53786. (D) The venn plot showing intersection genes of PPI hub gene and prognostic TPGs. PPI, protein-protein interaction.

405 **Figure 3 TPGs signature prognostic model was constructed.**

406 (A) Three genes enrolled in the prognostic model. (B) The patients in GSE53786 dataset were 407 divided into high and low-risk group according to the median riskScore based on the 408 prognostic model. (C) High-risk group had worse prognosis than low-risk group. (D) The 409 heapmap showing expression discrepancy of the three genes. (E) Survival analysis revealed 410 that high-risk group had poor prognosis in GSE53786 dataset. (F) The ROC curve showed 411 that the prognostic model performed well in predicting 1-year, 3-year and 5-year prognosis in 412 GSE53786 dataset. (G) Tumor purity was positively correlated with riskScore in GSE53786 413 dataset. ROC, receiver operating characteristic.

Figure 4 The riskScore of three TPGs signature prognostic model was an independent prognostic factor in DLBCL patients.

(A) Survival analysis results in GSE32918 dataset was consistent to that of GSE53786 dataset.
(B) The prognostic model also did well in GSE32918 dataset. (C) High-risk group in
GSE53786 dataset contained more ABC type DLBCL, while low-risk group contained more
GCB type DLBCL. (D) The ECOG performance of two groups (GSE53786 dataset) showed
no statistical difference. (E) More patients in high-risk group were at Stage III or Stage IV,

and less patients were at Stage I, compared with low-risk group, although no statistical significance was shown (GSE53786 dataset). (F) High-risk group had higher LDH ratio (GSE53786 dataset). (G) The riskScore was associated with poor prognosis of DLBCL patients in GSE53786 dataset. (H) The riskSocre was an independent prognostic factor for DLBCL patient. * p < 0.05, ** p < 0.01, ns, not significant. ABC, activated B cell; GCB, germinal center B cell; ECOG, Eastern Cooperative Oncology Group; LDH, lactic dehydrogenase.

428 Figure 5 The analysis of CHCAMS cohort.

429 (A) The representative image of VCAN staining of high and low expression groups and the 430 survival analysis based on VCAN expression. (B) The representative image of CD3G staining 431 of high and low CD3G+ T cells ratio groups and the survival analysis based on CD3G+ T 432 cells ratio. (C) The representative image of C1QB staining of high and low expression group 433 and the survival analysis based on C1QB expression. (D) The representative image of CD68 434 staining of high and low CD68+ macrophages ratio groups and the survival analysis based on 435 CD68+ macrophages ratio. (E) The representative image of CD8 staining of high and low 436 CD8+ T cells ratio groups and the survival analysis based on CD8+ T cells ratio. (F) The 437 representative image of CD4 staining of high and low CD4+ T cells ratio groups and the 438 survival analysis based on CD4+ T cells ratio. (G) The correlation between VCAN, CD3G+ T 439 cells ration, C1QB and CD68+ macrophages, CD8+ T cells and CD4+ T cells ratio. "X" 440 means no statistical significance. (H–I) GSEA analysis based on the differentially expressed 441 genes between high-risk and low-risk group in GSE53786 and GSE32918. (J) The CD3G+ T 442 cells infiltration varied from colon to testis originating DLBCL in male. (K) The VCAN 443 expression level was different between intra- and extra-lymph node DLBCL.

Figure 6 Drug sensitivity prediction revealed therapeutic candidates for high-risk group.

(A) Drug sensitivity prediction results with statistical significance in GSE53786 dataset. (B)
Drug sensitivity prediction results with statistical significance in GSE53786 dataset.
According to "oncoPredict" algorithm, sensitivity score indicates IC50 of drugs, with higher
sensitivity score indicating lower sensitivity.

- 449 Supplementary Figure 1 Flow chart and study design of this research.
- 450 Supplementary Figure 2 The correlation between tumor purity and prognosis and

451 riskScore in GSE32918 dataset.

(A) High ESTIMATE-Score group had better prognosis. (B) ESTIMATE-Score was
negatively associated with riskScore. Note: ESTIMATE-Score manifests the tumor purity,
with high ESTIMATE-Score indicating low tumor purity and high immune and stromal
components. Because the GSE32918 datasets were sequenced with illumina platform, the
ESTIMATE algorithm only provided ESTIMATE Score to represent the tumor purity.

457 Supplementary Figure 3 The immunoenvironment analysis and clinicopathological
 458 analysis of CHCAMS cohort and GEO datasets.

- 459 (A) The ratio of CD68+ macrophages, CD8+ T cells and CD4+ T cells in CHCAMS cohort.
- 460 (B-D) The correlation between VCAN, CD3G+ T cells, C1QB and types of DLBCL in
- 461 CHCAMS cohort. (E-K) The correlation between VCAN, CD3G+ T cells, C1QB and
- 462 DCBCL origination in CHCAMS cohort. "Location to LN" means the relative location of the

tumor to lymph node, that is, intra-lymph node or extra-lymph node. (L–M) The predicted M1

- and M2 macrophages proportion in GSE53786 dataset. (N-O) The predicted M1 and M2
- 465 macrophages proportion in GSE32918 dataset. (P) The validation of M1 (CD32+ cells) and

466 M2(CD206+ cells) macrophages infiltration in DLBCL in CHCAMS cohort. **p < 0.01,

467 ***p < 0.001.

469 Refere	ences:
------------	--------

470	1.	Alaggio, R., et al., The 5th edition of the World Health Organization Classification of
471		Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia, 2022. 36(7): p.
472		1720-1748.
473	2.	Sehn, L.H. and G. Salles, <i>Diffuse Large B-Cell Lymphoma.</i> N Engl J Med, 2021.
474		384 (9): p. 842-858.

- 475 **3**. Hans, C.P., et al., *Confirmation of the molecular classification of diffuse large B-cell*
- 476 *lymphoma by immunohistochemistry using a tissue microarray.* Blood, 2004. 103(1): p.
- 477 **275-82**.
- 478 **4**. Autio, M., et al., *Immune cell constitution in the tumor microenvironment predicts the*
- 479 *outcome in diffuse large B-cell lymphoma.* Haematologica, 2021. **106**(3): p. 718-729.
- 480 5. Joyce, J.A. and J.W. Pollard, *Microenvironmental regulation of metastasis*. Nat Rev
 481 Cancer, 2009. 9(4): p. 239-52.
- 482 6. Steen, C.B., et al., *The landscape of tumor cell states and ecosystems in diffuse large*483 *B cell lymphoma.* Cancer Cell, 2021. **39**(10): p. 1422-1437.e10.
- 484 7. Ciavarella, S., et al., *Dissection of DLBCL microenvironment provides a gene*
- 485 *expression-based predictor of survival applicable to formalin-fixed paraffin-embedded*486 *tissue.* Ann Oncol, 2018. 29(12): p. 2363-2370.
- 487 8. Ennishi, D., et al., *Toward a New Molecular Taxonomy of Diffuse Large B-cell*488 *Lymphoma*. Cancer Discov, 2020. 10(9): p. 1267-1281.
- 489 9. Miyawaki, K., et al., A germinal center-associated microenvironmental signature
 490 reflects malignant phenotype and outcome of DLBCL. Blood Adv, 2022. 6(7): p.

491 **2388-2402**.

- 492 10. Schmitz, R., et al., Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma. N
- 493 Engl J Med, 2018. **378**(15): p. 1396-1407.
- 11. Lou, X., et al., CCL8 as a promising prognostic factor in diffuse large B-cell lymphoma
- 495 via M2 macrophage interactions: A bioinformatic analysis of the tumor
- 496 *microenvironment.* Front Immunol, 2022. **13**: p. 950213.
- 497 12. Gong, Z., J. Zhang, and W. Guo, *Tumor purity as a prognosis and immunotherapy* 498 *relevant feature in gastric cancer.* Cancer Med, 2020. 9(23): p. 9052-9063.
- Lou, S., et al., *Comprehensive Characterization of Tumor Purity and Its Clinical Implications in Gastric Cancer.* Front Cell Dev Biol, 2021. 9: p. 782529.
- 501 14. Zhao, Y., et al., *Tumor purity-associated genes influence hepatocellular carcinoma*
- 502 prognosis and tumor microenvironment. Front Oncol, 2023. 13: p. 1197898.
- 503 15. Zhang, C., et al., Tumor Purity as an Underlying Key Factor in Glioma. Clin Cancer
- 504 Res, 2017. 23(20): p. 6279-6291.
- 505 16. Yoshihara, K., et al., *Inferring tumour purity and stromal and immune cell admixture*506 *from expression data*. Nat Commun, 2013. 4: p. 2612.
- 507 17. Wang, M., D. Windgassen, and E.T. Papoutsakis, *Comparative analysis of*
- 508 transcriptional profiling of CD3+, CD4+ and CD8+ T cells identifies novel immune
- 509 *response players in T-cell activation.* BMC Genomics, 2008. **9**: p. 225.
- 510 18. Baghy, K., et al., *Proteoglycans in liver cancer*. World J Gastroenterol, 2016. 22(1): p.
 511 379-93.
- 512 19. Wight, T.N., *Provisional matrix: A role for versican and hyaluronan*. Matrix Biol, 2017.

- 513 **60-61**: p. 38-56.
- 514 20. Fujii, K., et al., *Versican upregulation in Sézary cells alters growth, motility and* 515 *resistance to chemotherapy.* Leukemia, 2015. **29**(10): p. 2024-32.
- 516 21. Wight, T.N., et al., *Versican-A Critical Extracellular Matrix Regulator of Immunity and*
- 517 *Inflammation.* Front Immunol, 2020. 11: p. 512.
- 518 22. Song, J., et al., Versican enrichment predicts poor prognosis and response to
- 519 adjuvant therapy and immunotherapy in gastric cancer. Front Immunol, 2022. 13: p.
- 520 **960570**.
- 521 23. Wang, M.Q., et al., *VCAN, expressed highly in hepatitis B virus-induced hepatocellular*
- 522 carcinoma, is a potential biomarker for immune checkpoint inhibitors. World J
 523 Gastrointest Oncol, 2022. 14(10): p. 1933-1948.
- 524 24. Yang, H., et al., Prognostic and immune-related value of complement C1Q (C1QA,
- 525 *C1QB, and C1QC) in skin cutaneous melanoma.* Front Genet, 2022. 13: p. 940306.
- 526 25. Li, Z., et al., Differentiation-related genes in tumor-associated macrophages as
- 527 *potential prognostic biomarkers in non-small cell lung cancer.* Front Immunol, 2023.
- 528 **14**: p. 1123840.
- 529 26. Mangogna, A., et al., *Prognostic Implications of the Complement Protein C1q in* 530 *Gliomas.* Front Immunol, 2019. **10**: p. 2366.
- Jiang, J., et al., *Identification of TYROBP and C1QB as Two Novel Key Genes With Prognostic Value in Gastric Cancer by Network Analysis.* Front Oncol, 2020. 10: p.
 1765.
- 534 28. Chen, L.H., et al., Complement C1q (C1qA, C1qB, and C1qC) May Be a Potential

- 535 Prognostic Factor and an Index of Tumor Microenvironment Remodeling in
- 536 *Osteosarcoma.* Front Oncol, 2021. 11: p. 642144.
- 537 29. Zheng, Y., et al., *IRF4-activated TEX41 promotes the malignant behaviors of*
- 538 melanoma cells by targeting miR-103a-3p/C1QB axis. BMC Cancer, 2021. 21(1): p.
- 539 **1339**.
- S40 30. Chen, Z., et al., A Machine Learning Model to Predict the Triple Negative Breast
 S41 Cancer Immune Subtype. Front Immunol, 2021. 12: p. 749459.
- 542 31. Wang, Q., P. Li, and W. Wu, A systematic analysis of immune genes and overall
- 543 *survival in cancer patients.* BMC Cancer, 2019. **19**(1): p. 1225.
- 544 32. Wang, J., et al., Establishment and validation of immune microenvironmental gene
- 545 signatures for predicting prognosis in patients with head and neck squamous cell
 546 carcinoma. Int Immunopharmacol, 2021. 97: p. 107817.
- 547 33. Zhang, Y., et al., GM-CSF enhanced the effect of CHOP and R-CHOP on inhibiting
- 548 diffuse large B-cell lymphoma progression via influencing the macrophage polarization.
- 549 Cancer Cell Int, 2021. 21(1): p. 141.
- 550 34. Croci, G.A., et al., SPARC-positive macrophages are the superior prognostic factor in
- 551 the microenvironment of diffuse large B-cell lymphoma and independent of MYC
- 552 rearrangement and double-/triple-hit status. Ann Oncol, 2021. 32(11): p. 1400-1409.
- 553 35. Farhood, B., M. Najafi, and K. Mortezaee, *CD8(+) cytotoxic T lymphocytes in cancer*554 *immunotherapy: A review.* J Cell Physiol, 2019. 234(6): p. 8509-8521.
- 555 36. Roussel, M., et al., Functional characterization of PD1+TIM3+ tumor-infiltrating T cells
- 556 *in DLBCL and effects of PD1 or TIM3 blockade.* Blood Adv, 2021. **5**(7): p. 1816-1829.

- 557 37. Xu-Monette, Z.Y., et al., Immune Profiling and Quantitative Analysis Decipher the
- 558 Clinical Role of Immune-Checkpoint Expression in the Tumor Immune
- 559 Microenvironment of DLBCL. Cancer Immunol Res, 2019. 7(4): p. 644-657.
- 560 38. Hirani, P., et al., *Targeting Versican as a Potential Immunotherapeutic Strategy in the*
- 561 *Treatment of Cancer.* Front Oncol, 2021. 11: p. 712807.
- 562 **39**. Huang, X.Y., et al., *Bioinformatics analysis of the prognosis and biological significance*
- 563 of VCAN in gastric cancer. Immun Inflamm Dis, 2021. 9(2): p. 547-559.











